G G Zhanel
Affiliation: University of Manitoba
- Zhanel G, Trapp S, Gin A, DeCorby M, Lagacé Wiens P, Rubinstein E, et al. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections. Expert Rev Anti Infect Ther. 2008;6:67-81 pubmed publisher..Both telavancin and dalbavancin show promise as alternative treatments for patients with serious infections caused by resistant Gram-positive pathogens. ..
- Zhanel G, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban D, et al. Comparative review of the carbapenems. Drugs. 2007;67:1027-52 pubmed..aeruginosa than meropenem. Clinical trials are required to establish the efficacy and safety of doripenem in moderate to severe infections, including nosocomial infections. ..
- Zhanel G, Wang X, Nichol K, Nikulin A, Wierzbowski A, Mulvey M, et al. Molecular characterisation of Canadian paediatric multidrug-resistant Streptococcus pneumoniae from 1998-2004. Int J Antimicrob Agents. 2006;28:465-71 pubmed..In conclusion, paediatric MDR S. pneumoniae simultaneously resistant to penicillin, erythromycin and T/S are genetically similar and disseminating across Canada. Prevnar provides excellent coverage of paediatric MDR S. pneumoniae. ..
- Zhanel G, Rossnagel E, Nichol K, Cox L, Karlowsky J, Zelenitsky S, et al. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. a. J Antimicrob Chemother. 2011;66:1301-5 pubmed publisher..Ceftaroline ƒT(> MIC) of ? 92% (ceftaroline MICs, ? 1 mg/L) was bactericidal (? 3 log?? killing) against MSSA, CA-MRSA, HA-MRSA, hVISA, VISA and VRSA at 12 and 24 h. ..
- Karlowsky J, Adam H, Kosowan T, Baxter M, Nichol K, Laing N, et al. PCR ribotyping and antimicrobial susceptibility testing of isolates of Clostridium difficile cultured from toxin-positive diarrheal stools of patients receiving medical care in Canadian hospitals: the Canadian Clostridium difficile Surveillance Study. Diagn Microbiol Infect Dis. 2018;91:105-111 pubmed publisher..5 ?g/mL; lowest maximum MIC, 2 ?g/mL) of eight antimicrobial agents tested and was the most active agent against each of the five commonest ribotypes (MIC90, 0.25-1 ?g/mL). ..
- Zhanel G, Hartel E, Adam H, Zelenitsky S, Zhanel M, Golden A, et al. Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia. Drugs. 2016;76:1737-1757 pubmed..Overall, the in vitro activity, clinical efficacy, tolerability, and safety profile of solithromycin demonstrated to date suggest that it continues to be a promising treatment for CABP. ..
- Zhanel G, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, et al. Ceftolozane/tazobactam: a novel cephalosporin/?-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014;74:31-51 pubmed publisher..aeruginosa infections with this agent. Currently, ceftolozane/tazobactam is being evaluated in three phase III trials for the treatment of cUTI, cIAI, and VABP. ..
- Zhanel G, Karlowsky J, Schwartz B, Jensen S, Hoban D. Mecillinam activity compared to ampicillin, trimethoprim/sulfamethoxazole, ciprofloxacin and nitrofurantoin against urinary tract isolates of gram-negative bacilli. Chemotherapy. 1998;44:391-6 pubmed..9% of ampicillin-resistant E. coli and 95.9% of trimethoprim/sulfamethoxazole-resistant E. coli. We conclude that mecillinam should be reevaluated for potential use in the treatment of community-acquired urinary tract infections. ..
- Zhanel G, Baxter M, Adam H, Sutcliffe J, Karlowsky J. In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015. Diagn Microbiol Infect Dis. 2018;91:55-62 pubmed publisher..Eravacycline demonstrates promising activity against recent clinical Gram-negative and Gram-positive bacteria, including multidrug-resistant pathogens. ..
- Zhanel G, Parkinson K, Higgins S, Denisuik A, Adam H, Pitout J, et al. Pharmacodynamic activity of fosfomycin simulating urinary concentrations achieved after a single 3-g oral dose versus Escherichia coli using an in vitro model. Diagn Microbiol Infect Dis. 2017;88:271-275 pubmed publisher..Our data help to explain the high (>90%) microbiological and clinical cure rates achieved with fosfomycin when used as a single 3-g oral dose to treat patients with acute uncomplicated cystitis. ..
- Karlowsky J, Walkty A, Baxter M, Arhin F, Moeck G, Adam H, et al. In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015. Diagn Microbiol Infect Dis. 2017;87:349-356 pubmed publisher..06, 0.06, 0.06, respectively) and 144 isolates of MRSA (0.12, 0.06, 0.06, respectively) collected in 2015. ..
- Zhanel G, Cheung D, Adam H, Zelenitsky S, Golden A, Schweizer F, et al. Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. Drugs. 2016;76:567-88 pubmed publisher..Eravacycline is a promising intravenous and oral fluorocycline that may offer an alternative treatment option for patients with serious infections, particularly those caused by multidrug-resistant Gram-negative pathogens. ..
- Zhanel G, Johanson C, Laing N, Hisanaga T, Wierzbowski A, Hoban D. Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary. Antimicrob Agents Chemother. 2005;49:1943-8 pubmed..In conclusion, free-telithromycin concentrations in serum and ELF simulating C(max)/MIC > or = 3.5 and AUC(0-24 h)/MIC > or = 25 completely eradicated (> or =4 log(10) killing) macrolide-resistant S. pneumoniae at 24 and 48 h. ..
- Zhanel G, Karlowsky J, Harding G, Carrie A, Mazzulli T, Low D, et al. A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. The Canadian Urinary Isolate Study Group. Antimicrob Agents Chemother. 2000;44:1089-92 pubmed..0, 18.9, 7.4, 0.1, and 1.2%, respectively. The majority of E. coli isolates resistant to ampicillin, trimethoprim-sulfamethoxazole, or ciprofloxacin were susceptible (MIC, <16 microg/ml) to mecillinam. ..
- Zhanel G, Decorby M, Adam H, Mulvey M, McCracken M, Lagacé Wiens P, et al. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008). Antimicrob Agents Chemother. 2010;54:4684-93 pubmed publisher..The prevalence of MRSA was 27.0% (of which genotypically 27.6% were CA-MRSA), while ESBL-producing E. coli occurred in 4.9% of isolates. An MDR phenotype was common in P. aeruginosa. ..
- Zhanel G, Karlowsky J, Rubinstein E, Hoban D. Tigecycline: a novel glycylcycline antibiotic. Expert Rev Anti Infect Ther. 2006;4:9-25 pubmed..e., nausea, vomiting and diarrhea) the most commonly reported. Tigecycline is a promising new broad-spectrum parenteral monotherapy for the treatment of patients with Gram-positive and -negative bacterial infections. ..
- Zhanel G, Lawrence C, Adam H, Schweizer F, Zelenitsky S, Zhanel M, et al. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Drugs. 2018;78:65-98 pubmed publisher..Finally, increased activity of imipenem-relebactam against P. aeruginosa may be of clinical benefit to patients with suspected or documented P. aeruginosa infections. ..
- Zhanel G, DeCorby M, Nichol K, Wierzbowski A, Baudry P, Karlowsky J, et al. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006. Diagn Microbiol Infect Dis. 2008;62:67-80 pubmed publisher..aeruginosa), respectively...
- Zhanel G, Karlowsky J, Harding G, Balko T, Zelenitsky S, Friesen M, et al. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob Agents Chemother. 1997;41:863-5 pubmed..12 microg/ml) (n = 10), and was inactive against C. neoformans (MIC90, >10.24 microg/ml) (n = 15) and B. dermatitidis (MIC90, 16 microg/ml) (n = 29)...